MetrionAIIntelligence

Sign in Register

Home Watchlist Market News High Impact News Market Movers Screener Portfolio Calculators Heatmap Compare Calendars Crypto Forex Macro Maps

Research Tools

Financial Analysis Analyst Estimates Insider Trading Market Guide Trading Ideas Charts

Financial Analysis

Highlights Income Statement Balance Sheet Cash Flow Multiples Profitability

Loading market dashboard

My Watchlist

Sign in to track securities

Create an account to keep a persistent watchlist.

Home High Impact News Market Movers

Loading news article

Back to markets

zacks.com/March 31, 2026 at 1:16 PMSNY

Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease

SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.

Open original source